Pasithea Therapeutics Corp.

KTTA Nasdaq CIK: 0001841330

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH, FL, 33139
Mailing Address 1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH, FL, 33139
Phone (702) 514-4174
Fiscal Year End 1231
EIN 851591963

Financial Overview

FY2025

$60.24M
Total Assets
$5.02M
Total Liabilities
$55.22M
Stockholders' Equity
$55.16M
Cash & Equivalents
$-2.91
EPS

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 30, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 27, 2026 View on SEC
8-K Current report of material events February 20, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 17, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 12, 2026 View on SEC
8-K Current report of material events January 28, 2026 View on SEC
DEF 14A Definitive proxy statement December 29, 2025 View on SEC
8-K Current report of material events December 15, 2025 View on SEC

Annual Reports

10-K March 30, 2026
  • PAS-004 shows promising safety profile with no serious side effects in early trials.
  • Strategic pivot to focus exclusively on PAS-004 to optimize cash runway.
View Analysis

Material Events

8-K Financial Distress February 20, 2026
High Impact
  • Pasithea Therapeutics Corp. received a Nasdaq notice for failing to meet the minimum $1.00 bid price requirement.
  • The company has 180 calendar days (until August 19, 2026) to regain compliance by maintaining a $1.00 stock price for 10 consecutive business days.
View Analysis
8-K Legal Issue December 15, 2025
High Impact
  • Pasithea Therapeutics Corp. successfully resolved a major issue with the Nasdaq stock exchange.
  • The company has officially regained compliance with Nasdaq's minimum bid price rule ($1.00 per share).
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.